Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive drugs, such as iodobenzylguanidine meta-I131, may carry radiation
directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as
topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. A stem cell transplant may be able to
replace the cells that were destroyed by iodobenzylguanidine meta-i131 and topotecan
hydrochloride.
PURPOSE: This phase II trial is studying the side effects of iodobenzylguanidine meta-I131
given together with topotecan hydrochloride and to see how well it works in treating young
patients with refractory or relapsed metastatic neuroblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Oscar Lambret
Collaborators:
National Cancer Institute, France Novartis Pharmaceuticals